This review outlines computational methods from 2022 to 2025 for detecting multiple cancers from blood-based cell-free DNA. It evaluates fragmentomics and epigenetic analysis, covering statistical, machine learning, and deep learning approaches, with a focus on biological interpretability, validation, and clinical readiness. Multimodal ensemble methods show the highest promise for clinical use, but standardized evaluation protocols are needed for reliable comparison and future progress.